Protalix BioTherapeutics (PLX) Finished Goods (2012 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Finished Goods of $15.4 million for Q1 2026, up 119.15% year-over-year from $7.0 million in Q1 2025, and up 48.29% quarter-over-quarter from $10.4 million in Q4 2025.
Protalix BioTherapeutics (PLX) Finished Goods (2012 - 2026) Analysis & Trends
Protalix BioTherapeutics' Finished Goods history runs 10 years deep, the most recent figure standing at $15.4 million for Q1 2026.
- In Q1 2026, Finished Goods rose 119.15% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (up 119.15% YoY), while the FY2025 annual figure was $10.4 million, up 90.38% from the prior year.
- Finished Goods for Q1 2026 stood at $15.4 million, up from $10.4 million in the prior quarter.
- The five-year high for Finished Goods was $15.4 million in Q1 2026, with the low at $706000.0 in Q3 2024.
- The 5-year median for Finished Goods is $9.2 million (2024), against an average of $9.0 million.
- The sharpest annual moves came in 2024 and 2025: Finished Goods tumbled 91.46% in 2024, then surged 1446.32% in 2025.
- Protalix BioTherapeutics' Finished Goods stood at $10.6 million in 2022, then slumped by 45.24% to $5.8 million in 2023, then decreased by 6.28% to $5.4 million in 2024, then surged by 90.38% to $10.4 million in 2025, then surged by 48.29% to $15.4 million in 2026.
- Business Quant data shows PLX's Finished Goods at $15.4 million in Q1 2026, $10.4 million in Q4 2025, and $10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | Protalix BioTherapeutics | 191.57 Mn | 150.91 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.96 Mn |
| Mar 31, 2026 | 15.38 Mn |
| Dec 31, 2025 | 10.37 Mn |
| Sep 30, 2025 | 10.92 Mn |
| Jun 30, 2025 | 8.63 Mn |
| Mar 31, 2025 | 7.02 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Sep 30, 2024 | 706,000.00 |
| Jun 30, 2024 | 5.54 Mn |
| Mar 31, 2024 | 9.15 Mn |
| Dec 31, 2023 | 5.81 Mn |
| Sep 30, 2023 | 8.27 Mn |
| Jun 30, 2023 | 11.97 Mn |
| Mar 31, 2023 | 14.46 Mn |
| Dec 31, 2022 | 10.62 Mn |
| Sep 30, 2022 | 8.28 Mn |
| Jun 30, 2022 | 9.91 Mn |
| Mar 31, 2022 | 10.16 Mn |
| Dec 31, 2021 | 11.53 Mn |
| Sep 30, 2021 | 8.05 Mn |